Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase 1 trial (Annals of Neurology (2007) (399-495))

Amit Bar-Or, Peter A.J. Calabresi, Douglas Arnold, Clyde Markowitz, Stuart Shafer, Lloyd H. Kasper, Emmanuelle Waubant, Suzanne Gazda, Robert J. Fox, Michael Panzara, Neena Sarkar, Sunil Agarwal, Craig H. Smith

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Number of pages1
JournalAnnals of neurology
Volume63
Issue number6
DOIs
StatePublished - Jun 1 2008
Externally publishedYes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Bar-Or, A., Calabresi, P. A. J., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., Sarkar, N., Agarwal, S., & Smith, C. H. (2008). Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase 1 trial (Annals of Neurology (2007) (399-495)). Annals of neurology, 63(6). https://doi.org/10.1002/ana.21441